Two Cases of Acute Macular Neuroretinopathy Associated with the Adenovirus-based COVID-19 Vaccine Vaxzevria (Astrazeneca). (4th July 2022)

• Record Type: Journal Article
• Authors: Franchi, Alexander; Rauchegger, Teresa; Palme, Christoph; Frede, Katharina; Haas, Gertrud; Blatsios, Georgios; Kralinger, Martina; Zehetner, Claus
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 5(2022)
• Page Start: 1234
• Page End: 1239
• Publication Date: 2022-07-04
• Subjects: Acute macular neuroretinopathy -- vaccination -- SARS-CoV-2 -- COVID-19 -- vaxzevria; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2022.2027463
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To report two cases of acute macular neuroretinopathy (AMN) in young female patients following the administration of the adenovirus-based coronavirus disease 2019 (COVID-19) vaccine Vaxzevria (AstraZeneca). Methods: Spectral-domain optical coherence tomography and infrared imaging were used to confirm the diagnosis of AMN. Results: Both patients showed a parafoveal hyperreflective band in the outer nuclear layer, disruption of the ellipsoid and interdigitation zones of the photoreceptor layers, and correlating hyporeflective areas on the near-infrared images. Both patients presented with flu-like fever and sudden onset of fortifications within 48 hours of vaccination. One patient showed altered flow in the deep capillary plexus and highly elevated thrombotic parameters. Conclusion: We report a possible association between immune-mediated AMN and the administration of adenovirus-based COVID-19 vaccine Vaxzevria.